{"entity":{"id":"nct03486873","kind":"trial","name":"Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pemb","aka":[],"tldr":"A phase 3 trial of Favezelimab run by Merck Sharp & Dohme LLC, now recruiting.","summary":"Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587) is a phase 3 interventional study registered as NCT03486873 by Merck Sharp & Dohme LLC, with 3500 participants planned, started 2018-08-21. Conditions listed: Solid Tumors, Hematologic Malignancies. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT03486873","url":"https://clinicaltrials.gov/study/NCT03486873"}],"tags":["ctgov-ingest"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":["favezelimab"],"companies":["merck"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT03486873","phase":"3","setting":"A Multicenter, Open-label, Phase 3 Study to Evaluate the Long-term Safety and Efficacy in Participants Who Are Currently on Treatment or in Follow-up in Studies That Include Pembrolizumab","sponsor":"Merck Sharp & Dohme LLC","enrolled":3500,"outcomes":[]},"route":"/trials/nct03486873/","neighbours":{"drug":[{"id":"favezelimab","kind":"drug","name":"Favezelimab","route":"/drugs/favezelimab/"}],"company":[{"id":"merck","kind":"company","name":"Merck & Co. (MSD)","route":"/companies/merck/"}]}}